Evidence map›Paper›PMID 16145097›Full record

Trial reportJournal of clinical microbiology2005

Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.

M N Austin, R H Beigi, L A Meyn, S L Hillier

Registry-linked trialOpen access · greenAbstract readClinical TrialComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03917134 (Efficacy of the Use of Metronidazole After Laparoscopic Hysterectomy for the Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess. Multicentric Triple-blind Randomized Controlled Trial), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03917134 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Efficacy of the Use of Metronidazole After Laparoscopic Hysterectomy for the Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess. Multicentric Triple-blind Randomized Controlled Trial

TypeinterventionalSponsorCES UniversityRan2019 to 2020Enrolled600ConditionsHysterectomy, Cellulitis, Vaginosis, AbscessArmscephalosporin + Metronidazole Vaginal, cephalosporin + Placebos
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Bacterial vaginosis.Nature reviews. Disease primers · 2025
    Review
  9. Article
  10. Article
  11. Molecular Exploration ofPathogens (Basel, Switzerland) · 2024
    Article
  12. Article
  13. Article
  14. The Role ofPathogens (Basel, Switzerland) · 2024
    Review
  15. Article
  16. Review
  17. Astodrimer sodium and bacterial vaginosis: a mini review.Archives of gynecology and obstetrics · 2022
    Review
  18. Preclinical Data on theAntimicrobial agents and chemotherapy · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

M N AustinMagee-Womens Research Institute, Pittsburgh, PA 15213-3180, USA.
R H Beigi
L A Meyn
S L Hillier
Magee-Womens Research Institute · USCase Western Reserve University · USUniversity of Pittsburgh · US

Funding

TRICHOMONAS VAGINALIS AND SLPI MUCOSAL DEFENSESU01AI047785 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L · 1999 to 2002
$1.8M
NIAID NIH HHS U01 AI047785NIAID NIH HHS U01 AI47785
6 · The paper itself

Abstract

To compare the frequencies, concentrations, and antimicrobial susceptibilities of vaginal microbes isolated from women with bacterial vaginosis (BV) before and after therapy, 119 nonpregnant women aged 18 to 45 with clinical and Gram stain evidence of BV were randomized to receive intravaginal clindamycin or metronidazole. Vaginal swabs were collected at baseline and 7 to 12 days, 35 to 45 days, and 70 to 90 days following therapy for quantitative vaginal culture. For the 99 women completing all four visits, statistical analyses were performed comparing differences in vaginal microflora between the two treatment arms and between visits in the same treatment group. Antimicrobial susceptibility testing using the agar dilution method was performed for anaerobic gram-negative rods. Although both therapies resulted in decreased colonization by Gardnerella vaginalis and Mycoplasma hominis, only metronidazole treatment resulted in a significant decrease in the frequency and concentration of Prevotella bivia and black-pigmented Prevotella species. Of the 865 anaerobic gram-negative rods evaluated for susceptibility, only 3 (0.3%) were resistant to metronidazole, whereas clindamycin resistance increased significantly for P. bivia and black-pigmented anaerobic gram-negative rods persisting following clindamycin therapy. Clindamycin-resistant subpopulations of P. bivia and black-pigmented Prevotella species emerged 7 to 12 days after therapy even among women colonized initially by clindamycin-susceptible strains. These resistant subpopulations persisted at high frequencies (42 to 50%) 70 to 90 days following therapy. The two topical agents for treatment of BV have differing microbiologic effects on the vaginal microflora. The emergence of clindamycin-resistant anaerobic gram-negative rods following therapy is of concern.

Indexed as

Administration, TopicalAdolescentAdultAnti-Bacterial AgentsBacteroidaceaeBacteroidaceae InfectionsClindamycinDrug Resistance, BacterialFemaleHumansMetronidazoleMicrobial Sensitivity TestsMiddle AgedTreatment OutcomeVaginaVaginosis, BacterialAnti-Bacterial AgentsClindamycinMetronidazole

Identifiers

PMID16145097
PMCPMC1234077
OpenAlexW2110994288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.